Status:
UNKNOWN
Laboratory Assessment of the Concentration of Direct Oral Anticoagulants in Patients With Atrial Fibrillation
Lead Sponsor:
Wuhan Asia Heart Hospital
Collaborating Sponsors:
Wuhan Asia General Hospital (http://wagh.com.cn)
Conditions:
Oral Anticoagulant
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
The incidence of thromboembolic and bleeding event associated with catheter ablation for atrial fibrillation(CAAF) varies from 0.9% to 5% during peri-operative period. Direct oral anticoagulants (DOAC...
Eligibility Criteria
Inclusion
- Patients with Non-valvular atrial fibrillation(NVAF) undergoing catheter ablation
- Direct oral anticoagulants (Rivaroxaban, Edoxaban or Dabigatran)are administered peri-operatively during catheter ablation.
Exclusion
- Patients who have taken direct oral anticoagulants or warfarin before admission.
- Cross-replacement of oral anticoagulants, such as taking dabigatran before surgery and replacing Rivaroxaban after surgery.
- Abnormal coagulation tests (prothrombin time, partial thrombin time, thrombin time, antithrombin activity).
- Pregnant and lactating women.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
1864 Patients enrolled
Trial Details
Trial ID
NCT04684056
Start Date
January 1 2021
End Date
December 31 2023
Last Update
December 24 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.